Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New applications of neuropeptide y

A neuropeptide, inflammatory response technology, applied in the field of medicine, can solve the problems of high incidence and mortality of heart failure, and achieve the effect of reducing myocardial infarction area, slowing myocardial remodeling, and improving cardiac dysfunction.

Active Publication Date: 2021-12-14
GUANGZHOU MEDICAL UNIV +1
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

"China Cardiovascular Disease Report 2018" reported that interventional treatment for coronary heart disease in mainland China in 2017 increased by 13% compared with 2016, but there is no effective treatment that can completely reverse myocardial remodeling, the incidence of heart failure and death after acute myocardial infarction rate is still high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New applications of neuropeptide y
  • New applications of neuropeptide y

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] 1. Experimental materials

[0067] (1) 129S2 / SvPasCrl mice: aged from 8 to 10 weeks, with a body weight of 20g to 22g; all operations on the experimental 129S2 / SvPasCrl mice were performed in accordance with the guidelines for the feeding and use of experimental animals issued by the National Institutes of Health ( National Institutes of Health publication number 85-23, revised 1996).

[0068] (2) Anesthetic and sedative drugs: ketamine (50mg / kg) and xylazine (50mg / kg).

[0069] (3) Neuropeptide Y (Neuropeptide Y, NPY) powder: purchased from Sigma, USA, prepared with 0.9% by mass saline. The preparation concentration of this embodiment includes 12.5 μg / kg, 25 μg / kg, 50 μg / kg and 100 μg / kg.

[0070] 2. Experimental method

[0071] (1) Mouse anesthesia:

[0072] Take 129S2 / SvPasCrl mice, inject ketamine (50 mg / kg) and xylazine (50 mg / kg) intraperitoneally according to the weight of the mice, and anesthetize the 129S2 / SvPasCrl mice.

[0073] (2) Construction of model ...

Embodiment 2

[0089] 1. Experimental materials

[0090] (1) 129S2 / SvPasCrl mice: aged from 8 to 10 weeks, with a body weight of 20g to 22g; all operations on the experimental 129S2 / SvPasCrl mice were performed in accordance with the guidelines for the feeding and use of experimental animals issued by the National Institutes of Health ( National Institutes of Health publication number 85-23, revised 1996).

[0091] (2) Anesthetic and sedative drugs: ketamine (50mg / kg) and xylazine (50mg / kg).

[0092] (3) Neuropeptide Y (Neuropeptide Y, NPY) powder: purchased from Sigma, USA, prepared with 0.9% by mass saline. The preparation concentration of this embodiment includes 12.5 μg / kg, 25 μg / kg, 50 μg / kg and 100 μg / kg.

[0093] 2. Experimental method

[0094] (1) Mouse anesthesia:

[0095] Take 129S2 / SvPasCrl mice, inject ketamine (50 mg / kg) and xylazine (50 mg / kg) intraperitoneally according to the weight of the mice, and anesthetize the 129S2 / SvPasCrl mice.

[0096] (2) Construction of model ...

Embodiment 3

[0112] 1. Experimental materials

[0113] (1) 129S2 / SvPasCrl mice: aged from 8 to 10 weeks, with a body weight of 20g to 22g; all operations on the experimental 129S2 / SvPasCrl mice were performed in accordance with the guidelines for the feeding and use of experimental animals issued by the National Institutes of Health ( National Institutes of Health publication number 85-23, revised 1996).

[0114] (2) Anesthetic and sedative drugs: ketamine (50mg / kg) and xylazine (50mg / kg).

[0115] (3) Neuropeptide Y (Neuropeptide Y, NPY) powder: purchased from Sigma, USA, prepared with 0.9% by mass saline. The preparation concentration of this embodiment includes 12.5 μg / kg, 25 μg / kg, 50 μg / kg and 100 μg / kg.

[0116] 2. Experimental method

[0117] (1) Mouse anesthesia:

[0118] Take 129S2 / SvPasCrl mice, inject ketamine (50 mg / kg) and xylazine (50 mg / kg) intraperitoneally according to the weight of the mice, and anesthetize the 129S2 / SvPasCrl mice.

[0119] (2) Construction of model ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new application of neuropeptide Y, which is mainly used for preparing the drug for myocardial remodeling after acute myocardial infarction. Verified by acute myocardial infarction model mice, neuropeptide Y can improve cardiac dysfunction, reduce myocardial infarct size, reduce myocardial fibrosis, reduce inflammation, and reduce myocardial cell structure damage, thereby reducing the mortality rate of acute myocardial infarction. Myocardial remodeling plays a protective role in myocardial infarction mice.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a new application of neuropeptide Y. Background technique [0002] Acute myocardial infarction is a common heart disease that rapidly causes extensive ischemic necrosis of the myocardium due to vascular blockage, often accompanied by severe morbidity and mortality, threatening human health and quality of life. Myocardial fibrosis, also known as myocardial calcification, refers to the excessive accumulation of collagen fibers and a significant increase in collagen concentration in the normal tissue structure of the myocardium. It is the main pathophysiological process of reverse myocardial remodeling after acute myocardial infarction, which can eventually lead to left heart failure insufficiency and heart failure. Reverse myocardial remodeling that occurs after acute myocardial infarction remains a major cause of morbidity and mortality. Therefore, reverse myocardial remodelin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P9/10
CPCA61K38/17A61P9/10
Inventor 余细勇蓝辉耀覃宇燕
Owner GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com